Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13525120 | 1.00 | CHRM5 (0.47) | CHRM5CHRM3SIGMAR1HSD17B10SLC6A9 | |
| SCHEMBL27404930 | 1.00 | CHRM5 (0.47) | CHRM5CHRM3SIGMAR1HSD17B10SLC6A9 | |
| SCHEMBL29299503 | 0.98 | CHRM5 (0.49) | CHRM5CHRM3SIGMAR1HSD17B10KMT2A | |
| Acetic Acid SCHEMBL26964860 | 0.92 | CHRM5 (0.50) | CHRM5CHRM3SIGMAR1HSD17B10SLC6A9 | |
| SCHEMBL13742551 | 0.92 | CHRM5 (0.53) | CHRM5CHRM3SIGMAR1KMT2AMEN1 | |
| SCHEMBL16800789 | 0.91 | SIGMAR1 (0.48) | CHRM5CHRM3SIGMAR1HSD17B10KMT2A | |
| SCHEMBL24247411 | 0.90 | CHRM5 (0.55) | CHRM5CHRM3SIGMAR1HSD17B10KMT2A | |
| SCHEMBL8038 | 0.90 | CHRM5 (0.55) | CHRM5CHRM3SIGMAR1HSD17B10KMT2A | |
| SCHEMBL29299554 | 0.90 | CHRM5 (0.50) | CHRM5CHRM3SIGMAR1HSD17B10SLC6A9 | |
| SCHEMBL472213 | 0.90 | CHRM5 (0.50) | CHRM5CHRM3SIGMAR1HSD17B10SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | CHRM5 2123/4885CHRM3 1728/4885SIGMAR1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.